Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) Dilutes Shareholders – Again

Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) shares dropped nearly 20% after the biotechnology firm announced the pricing of an underwritten offering of 2,640,000 shares of its common stock and warrants. The offering prices 1.32 million CLSN shares at $2.50 and each share is is being sold together with 0.50 warrants, with each whole warrant exercisable to purchase one whole share of common stock. The warrants have an exercise price of $3.00 per share, are not exercisable until six months after issuance and will terminate 5 years from the time each warrant is first exercisable. Celsion expects to raise $6.6 million before expenses and fees are deducted.

Celsion Corporation (NASDAQ:CLSN)

The announcement sent the shares gapping lower to open at $2.30 after closing on Thursday at $2.86. Twice during October CLSN stock had made runs to the $6 handle before retreating. Prior to Friday, the shares had experienced over ten trading days of consecutive losses.

Lawrenceville, NJ-based Celsion Corporation (NASDAQ:CLSN) is an oncology drug company that develops and commercializes directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers.

CLSN Stock Performance

On October 4, 2017 Maxim Group upgraded their rating on CLSN shares from a “Hold” to a “Buy” with a $7 price target. Two other investment firms have previously rated CLSN stock as a “Strong Buy”. The one-year consensus price target is $8.

However, shares of the biotech have not performed. Year-to-date shares are down over 45% and are down over 84% for the year. In the short-term shareholders have seen a bounce from the August-September trading range under $2 and their monthly performance is a positive 50% over the past month.

Celsion Corporation (NASDAQ:CLSN) has a consistent history of issuing shares and diluting shareholder equity. In 2012, there were 550,000 shares outstanding and that number has grown each year. In 2016 there were 1.85 million CLSN shares outstanding. Earnings have been just as frustrating for shareholders. Per share losses have been reported every year since 2012 and for 2016 the loss was (-$11.90) per share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

MediciNova, Inc. (NASDAQ:MNOV)

MediciNova, Inc. (NASDAQ:MNOV) Reports Topline Results

MediciNova, Inc. (NASDAQ:MNOV)

MediciNova, Inc. (NASDAQ:MNOV) shares fell 2.76% after the biopharmaceutical company reported topline results from its SPRINT-MS Phase 2B trials which investigated MN-166 for the treatment of multiple sclerosis. The lead drug candidate achieved its primary endpoints by demonstrating statistically significant reduction in the rate of progression in brain atrophy when compared to a placebo.

MediciNova, Inc. (NASDAQ:MNOV)

MN-166 Topline Results

The topline clinical trial results will be presented at the 7th Joint ECTRIMS*-ACTRIMS** Meeting in Paris on October 28, 2017, by Dr. Robert Fox, Staff Neurologist at the Cleveland Clinic.

Dr. Robert Fox commented, “This is an encouraging step forward in the development of treatments for progressive MS, which has historically been very difficult to treat.” Yuichi Iwaki, MD, Ph.D., President and Chief Executive Officer of MediciNova, Inc. commented, “This is a major epoch for patients. We will coordinate the next plan to complete our mission.”

MediciNova, Inc. (NASDAQ:MNOV) is currently trading in an uptrend after bouncing from its August lows of $4.40 a share. However, the stock has come under pressure in recent trading sessions after recording a new 52-week high of $7.85 a share. It faces immediate resistance at the $6.90 mark above which it could make a push for the 52-week high. The stock is currently rated as a strong buy by one analyst firm according to data compiled by Zacks Investment Research.

MediciNova Pipeline

MediciNova, Inc. (NASDAQ:MNOV) lead candidate drug MN-166 is an orally bioavailable, small-molecule phosphodiesterase designed to suppress pro-inflammatory cytokines to promote neurotrophic factors. The company acquired it from Kyori pharmaceuticals having been marketed in Japan and Korea since 1989.

MediciNova, Inc. (NASDAQ:MNOV) is currently focusing on MN-166 for the treatment of neurological disorders such as progressive MSM ALS and substance abuse. The company has completed the enrollment of patients in a Phase 2 clinical trial of MN166 in Methamphetamine Dependence.

“We are pleased that enrollment is now completed in the first study to evaluate MN-166’s (ibudilast) potential clinical utility for methamphetamine dependence. We look forward to the final results of the study which we expect by the first quarter of 2018,” said Mr. Iwaki

The company’s pipeline also includes MN-221 for the treatment of acute exacerbations of asthma and MN-029 for solid tumor cancers. MediciNova, Inc. (NASDAQ:MNOV) is currently engaged in strategic partnerships and other potential funding discussions to support the development of its clinical programs.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on MNOV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Neos Therapeutics Inc (NASDAQ:NEOS)

Neos Therapeutics Inc (NASDAQ:NEOS) Shares Rocket on Acquisition Offer

Neos Therapeutics Inc (NASDAQ:NEOS)

Neos Therapeutics Inc (NASDAQ:NEOS) stock boomed today after the company revealed that they are reviewing an unsolicited proposal to acquire the Texas-based drug company. NEOS stock ended yesterday at $7.30, then gapped up to open at $9.50 before hitting an inter-day high of $10.90 on a volume figure that was ten times the average. With two hours left in the trading day, NEOS shares are trading around the $10 handle.

Neos Therapeutics Inc (NASDAQ:NEOS)

Acquisition history

The current acquisition proposal is from PDL BioPharma Inc (NASDAQ:PDLI). On June 23, 2017 PDL made an offer to acquire Neos Therapeutics for $10.25 per share in cash. That offer was studied and subsequently rejected by the Neos Board of Directors. The, on July 31, 2017, PDL Biopharma made another unsolicited acquisition offer at the same price.  Following the second offer, Neos entered into a confidentiality agreement with PDL to facilitate discussions. Following these discussions, PDL again made a proposal to acquire Neos for $10.25 per share, in cash. At that time, PDL Biopharma acknowledged that Neos Therapeutics Inc (NASDAQ:NEOS) was likely more valuable than the offer price. In deciding to recommend a rejection of the PDL offer at $10.25 per share, the Neos Board considered the successful path the company is taking in executing its strategy.

NEOS Stock Performance

Shares of Neos Therapeutics Inc (NASDAQ:NEOS) have done well without the acquisition offerings. YTD, NEOS stock is up 25%, and is up over 12% for the quarter. Prior to today’s action, NEOS stock had a 52-week high of $9.60 and a 52-week low of $4.85.

Sales have improved considerably over the past three years. In 2014, the company reported $800,000 in sales which was followed by $3.8 million in 2015, and $9.2 million for 2016. Unfortunately, losses have been a noted area of concern among investors. In 2014, NEOS shares lost (-$1.76), followed by a per share loss of (-$2.07), and a larger loss of (-$5.19) for 2016.

Three investment firms follow Neos Therapeutics Inc (NASDAQ:NEOS). One rates NEOS stock as a “Strong Buy” one rates the shares a “Buy” and one rates the shares a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NEOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Sierra Oncology Inc. (NASDAQ:SRRA)

Sierra Oncology Inc. (NASDAQ:SRRA) Continues Uptrend

Sierra Oncology Inc. (NASDAQ:SRRA)

Sierra Oncology Inc. (NASDAQ:SRRA) traded higher after announcing the appointment of Dr. Andrew Allen to its Board of Directors. The stock was up by 12.6% in Wednesday’s trading session to end the day at $2.14 a share.

Sierra Oncology Inc. (NASDAQ:SRRA)

Wednesday’s rally saw the stock break a key resistance level at $1.90, affirming a bullish run that began in June. The stock is now up by more than 30% for the year as it continues to trade in a strong uptrend marked by a new 52-week high of $2.20 a share.

The appointment of Dr. Allen comes at a time when the clinical stage drug development company is advancing next-generation DNA Damage Response therapies for the treatment of patients with cancer. He joins the company with vast experience, having served as the Chief Executive of Gristone Oncology, and as Chief Medical Officer at Pharmion Corporation.

“I’ve been highly encouraged by the sophisticated approach Sierra is taking to developing SRA737, leveraging the rich biology of Chk1 synthetic lethality to incorporate prospective genomic profiling strategies to enhance patient selection in their trials and potentially improve their prospects for positive outcomes. I look forward to working closely with this outstanding team,” said Dr. Allen.

SRA737 Development

Sierra Oncology Inc. (NASDAQ:SRRA) will report preclinical data supporting the development of SRA737 at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer on October 26-30, 2017. The candidate drug is currently being investigated in two Phase 1 clinical trials in patients with advanced cancer.

The Chk1 inhibitor, SRA737 has been granted a selection patent by the U.S Patent and Trademark Office, which extends coverage until 2033. A similar European patent was issued in February. According to Sierra Oncology, the intellectual property establishes a solid foundation for the potential future commercialization of the promising candidate drug

“We anticipate generating additional intellectual property claims as we advance our DDR-focused research activities and our innovative genetics-driven clinical programs,” said CEO Nick Glover.

Q2 Financial Results

Separately, Sierra Oncology Inc. (NASDAQ:SRRA) reported a net loss of (-$10.3) million for the three months ended June 30, 2017, down from a net loss of (-$12.9) million reported a year ago. Cash and cash equivalent as of the end of the quarter stood at $125 million compared to $109 million as of December 31, 2016. According to the clinical stage company, the existing cash is sufficient to fund operations through mid-2019.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SRRA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Capricor Therapeutics Inc. (NASDAQ:CAPR)

Capricor Therapeutics Inc. (NASDAQ:CAPR) Spikes on Trial Expectations

Capricor Therapeutics Inc. (NASDAQ:CAPR)

Capricor Therapeutics Inc. (NASDAQ:CAPR) shares gained 9.09% after the clinical stage biotechnology company said it will make a presentation at the upcoming American Heart Association Scientific Sessions 2017 conference. The company is to present data from its HOPE-1 clinical trial, investigating CAP-1002 for the treatment of Duchenne Muscular Dystrophy in boys and young men.

Capricor Therapeutics Inc. (NASDAQ:CAPR)

Hope 1 Trial

The announcement appears to have triggered renewed interest in Capricor Therapeutics. The stock has been under pressure in recent trading sessions, after rising to multi-year highs of $3.50 a share. It is currently down by more than 10% for the year.

CAP-1002 is the company’s lead investigational product made up of allogeneic cardiosphere-derived cells. Capricor Therapeutics Inc. (NASDAQ:CAPR) has already reported meaningful improvements in cardiac and skeletal muscle function, on a six-month analysis of HOPE-1 trial.

“We look forward to sharing these new data at one of the world’s premier cardiovascular conferences and continuing our clinical development of CAP-1002 for the treatment of Duchenne muscular dystrophy,” said Linda Marbán, Ph.D., Capricor president, and CEO.

Capricor Therapeutics Inc. (NASDAQ:CAPR) plans to initiate patient enrollment for a randomized double-blind placebo-controlled HOPE-2 clinical trial, subject to regulatory approval. The trial will build on HOPE-1 trials that showed teens and young men in advanced stages of DMD experiencing meaningful improvements in cardiac and limb functions after a single dose of CAP-1002.

Duchenne muscular dystrophy is a devastating genetic disorder that results in muscle degeneration. The condition affects approximately 15,000 to 20,000 boys in the US and occurs in every 3,600 live male births across all races, cultures and countries. The medical condition leads to death before the age of 30.

Q2 Financial Results

Separately, Capricor Therapeutics Inc. (NASDAQ:CAPR) reported a net loss of (-$3.5) million or (-$0.16) per share for the second quarter, compared to a net loss of (-$4.7) million reported last year. The biotechnology company generated revenues of $996,000 for the quarter.

Capricor Therapeutics Inc. (NASDAQ:CAPR) exited the quarter with cash and cash equivalent of $12.3 million, compared to $16.2 million as of December 31, 2016. According to the company, the cash balance is sufficient to fund operations and meet all the company’s financial obligations through the second quarter of 2018.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CAPR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Cellect Biotechnology Ltd. (NASDAQ:APOP)

Cellect Biotechnology Ltd. (NASDAQ:APOP) Succeeds In Trial

Cellect Biotechnology Ltd. (NASDAQ:APOP)

Shares of Cellect Biotechnology Ltd. (NASDAQ:APOP) gained 10.8% after the stem cell developer achieved a major milestone with the conclusion a large study on the use of ApoGraft on stem cells derived from fat tissues. According to the company, the technology led to both an expansion of cells and an improvement in unique cell activity and attributes.

Cellect Biotechnology Ltd. (NASDAQ:APOP)

ApoGraft Study Results

According to Cellect Biotechnology Ltd. (NASDAQ:APOP) CEO, Dr. Shai Yarkoni, the study validates the use of the stem cell selection technology on a much wider array of companies and medical centers around the world. The technology could be of great help to the aesthetic and orthopedic industries where fat-derived stem cells are the main raw materials. Up until now, ApoGraft has mostly been used on blood cells. Buoyed by the positive results, Cellect Biotechnology plans to carry out clinical programs and licensing deals for the technology.

APOP Investor Reaction

The positive ApGraft study results helped strengthen investor confidence on the stock seen by the stock skyrocketing to $10 before it dropped to end Wednesday’s trading session at $8.82 a share. The stock is still in consolidation mode after failing on three attempts to rise above the $11 level.

However, the stock is up by more than 140% for the year as it continues to outperform the overall industry. Analysts and brokerage firms have already reacted to the positive trial results by initiating coverage of the stock.

HC Wainwright’s analyst Ram Selvaraju has initiated coverage of the stock with a ‘Buy’ rating. The analysts currently has a $14 price target on Cellect Biotechnology Ltd. (NASDAQ:APOP).

Strategic Alliances

Renewed investor interest on the stock comes on Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ:APOP) announcing that the significant milestone with ApoGraft technology, positions the company to pursue strategic alliances with other companies.

“This breakthrough finding is increasing our addressable market by an order of magnitude. We can now actively seek strategic alliances for the commercialization of ApoGraft™” in aesthetic medicine as well as orthopedic indications,” said Mr. Yarkoni.

Separately, Cellect Biotechnology Ltd. (NASDAQ:APOP) has confirmed the appointment of Dr. Ronit Bakimer-Kleiner as the new Chief Development Officer, replacing Dr. Yaron Pereg. She takes over with over twenty years of experience as a scientist and executive manager in the biotechnological industrial environment. Ronit previously served as the General Manager of Cognate Bioservices Ltd.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $APOP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Roka Bioscience Inc (NASDAQ:ROKA)

Roka Bioscience Inc (NASDAQ:ROKA) Catches Market by Surprise

Roka Bioscience Inc (NASDAQ:ROKA)

Roka Bioscience Inc (NASDAQ:ROKA) shares are up almost 50%, to $0.53, on heavy volume despite the lack of any publicly available news that could account for such extreme price action. The company’s last press release was in August of 2017.

Roka Bioscience Inc (NASDAQ:ROKA)

Roka Bioscience Inc (NASDAQ:ROKA) is a molecular diagnostics company that develops, markets, and sells advanced testing solutions for the food safety testing market. Their lead product is the Atlas® Detection Assay that integrates proprietary technologies into their Atlas System which automates all aspects of the diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.

Roka Bioscience Asset Sale

In August, Roka Bioscience Inc (NASDAQ:ROKA) announced that it entered into an asset purchase agreement with Rokabio, Inc., a wholly-owned subsidiary of Institute for Environmental Health, Inc., for the sale of substantially all of the assets of Roka Bioscience in an all-cash transaction for an aggregate purchase price of $17.5 million. Shares lost 9% the day the asset sale was announced and have been in a downward trajectory until a few days ago when shares gapped up and briefly traded about the psychologically important $2.50 level.

ROKA Stock Performance

The market capitalization of Roka Bioscience Inc (NASDAQ:ROKA) is less than $7 million with a float of 4.33 million shares. Investors have not had a good year. Year to date, ROKA shares have lost around 75% and, prior to today, lost over 34%. Reports have analyst’s consensus, one year price target at $10.

Sales have been improving every year. In 2012, the company reported just $100,000 in sales but that number improved each year and, in 2016, the company posted $7.2 million in sales. However, the upward momentum has not been seen in earnings. For 2016 the company reported a per share loss of (-$17.42), which was better than the loss of (-$21.18) reported in 2015, and the per share loss of (-$29.30) reported in 2014.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ROKA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Viking Therapeutics Inc. (NASDAQ:VKTX)

Viking Therapeutics Inc. (NASDAQ:VKTX)’s VK2809 Succeeds in Trial

Viking Therapeutics Inc. (NASDAQ:VKTX)

Viking Therapeutics Inc. (NASDAQ:VKTX) fell 5.36% after announcing positive results from an eight-week study of VK2809 as a novel treatment for a wide range of lipid disorders. Study results demonstrate lipid-lowering effects of the small molecule thyroid receptor, as well as anti-fibrotic benefits.

Viking Therapeutics Inc. (NASDAQ:VKTX)

VK2809 vs. Lipid Disorders

Treatment with VK2809 shows statistically significant reductions in liver triglycerides, liver cholesterol, and total lipids in treated animals, relative to vehicle controls. The trials also showed significant changes in expression of key genes associated with non-alcoholic Steatohepatitis development and progression.

“The observed changes in gene expression are exciting, as they corroborate the histologic improvements and suggest potential benefits of insulin sensitivity and metabolic control. VK2809’s therapeutic and safety profile continue to suggest a promising potential role in settings such as NASH and hyperlipidemia,” said CEO, Brian Lian.

Viking Therapeutics Inc. (NASDAQ:VKTX) is trading in an uptrend despite the 5% drop. The stock is up by more than 100% for the year and outperforming the overall industry. Renewed investor interest follows positive clinical trials of the company’s lead program VK2809 and VK0214.

According to Viking Therapeutics Inc. (NASDAQ:VKTX), VK2809 was well tolerated with no significant changes to liver functions it to test subjects relative to controls. VK2809 is a small molecule thyroid receptor that promises therapeutic potential in a range of lipid disorders.

Clinical data has already demonstrated that treatment with VK2809 could lead to a significant reduction in plasma triglycerides as well as LDL Cholesterol in subjects with mild hypercholesterolemia. Viking Therapeutics is currently evaluating it in a randomized, double-blind, placebo-controlled parallels group Phase 2 study.

VK0214 Development

In addition to VK2809, Viking Therapeutics Inc. (NASDAQ:VKTX) is also evaluating VK0214 on the treatment of X-linked adrenoleukodystrophy. The U.S. Food and Drug Administration has already granted the thyroid receptor beta Orphan Drug status.

Study results from a 25-week proof-of-concept study showed VK0214 led to statistically significant reductions in Plasma levels of very long chain fatty acids in treated animals. The therapy also demonstrated reductions in long chain fatty acids in tissues such as in the liver, brain, and spinal cord.

“The impressive effects on plasma VLCFAs strengthen our belief that activation of the thyroid beta receptor can lead to improved lipid processing. The reduction in tissue VLCFAs is particularly exciting, as it suggests a potential direct benefit on tissue-related toxicities,” said Brian Lian, Ph.D., chief executive officer of Viking.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VKTX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Pluristem Therapeutics Inc. (NASDAQ:PSTI),

Patent Pushes Pluristem Therapeutics Inc. (NASDAQ:PSTI) Higher

Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Pluristem Therapeutics Inc. (NASDAQ:PSTI), headquartered in Israel, established a new 52-week high today of $2.02 after the company announced that the European Patent Office has issued the company a patent titled, “Methods for Treating Radiation or Chemical Injury” for its PLX-R18 cell therapy. Volume for the biotechnology stock, up 9% in today’s trading, was heavy – over five times the daily average traded.

Pluristem Therapeutics Inc. (NASDAQ:PSTI),

Pluristem Patent

PLX-R18 is designed to treat bone marrow that is unable to produce enough blood cells due to a variety of causes, including acute radiation syndrome (ARS), certain cancers or cancer treatments, or immune-mediated bone marrow failure. Pluristem Therapeutics Inc. (NASDAQ:PSTI) currently holds several patents worldwide to cover placental 3D-expanded cells in the treatment of impaired hematopoietic systems when a bone marrow, cord blood, or peripheral blood transplant takes place.

Yaky Yanay, Co-CEO and President of Pluristem Therapeutics Inc. (NASDAQ:PSTI) stated “PLX-R18 cells have shown the ability to trigger regeneration of the hematopoietic system, thereby supporting the recovery and production of white blood cells, red blood cells and platelets. With its capabilities, we believe that PLX-R18 has the potential to treat a broad range of hematologic indications, which together constitute a substantial global market.”

PSTI Stock Performance

Three investment firms follow Pluristem Therapeutics Inc. (NASDAQ:PSTI) and all three rate PSTI shares as a “Strong Buy”. Their consensus, one year price target is $3.50. Investors have been hot on the stock. Over the past year PSTI stock is up over 30% and is up over 60% for the quarter. That upward momentum has resulted in a Relative Strength Index figure of 73 – prior to today’s trading. Traders believe that a figure above 70 represents an “overbought” condition.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) reported no sales for FY2017 after posting $2.8 million in 2016. The per share loss for FY2017 was (-$0.32) which followed a loss of (-$0.29) in 2016. Of note is a consistent expansion of the number of outstanding shares. For 2013, 55.48 million shares were outstanding. The dilutive expansion of the number of shares has increased every year and for 2017 the figure stands at 87.43 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PSTI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Strata Skin Sciences, Inc. (NASDAQ:SSKN) Rebounding

Strata Skin Sciences, Inc. (NASDAQ:SSKN)

Strata Skin Sciences, Inc. (NASDAQ:SSKN) stock is up over 20% today after a week that has seen the Skin Science company lose over 30% of its value. SSKN stock is experiencing heavy volume during this rebound as more than two million shares have traded hands for a stock that has an average daily volume of less than 200,000.

Strata Skin Sciences, Inc. (NASDAQ:SSKN)

Strata Skin Sciences

Strata Skin Sciences, Inc. (NASDAQ:SSKN), headquartered in Horsham, PA, is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; the STRATAPEN™ MicroSystem, marketed specifically for the intended use of micropigmentation; and Nordlys, a multi-technology aesthetic laser device.

SSKN Stock Review

Interestingly, the current market price for SSKN shares is below published figures of the company’s cash per share which is posted at $1.51. It has a book to share ratio of $4.99.

Yesterday SSKN shares hit a new 52-week low – hitting $1.10. Their 52-week high of $5.40 was achieved last April and the shares spiked again in May though not enough to establish a new high.

Sales have been increasing at a rapid pace. In 2014, Strata Skin Sciences, Inc. (NASDAQ:SSKN) reported sales at $900,000 but that number increased the following year and also in 2016 when the company posted a figure of $31.8 million. However losses have plagued the shareholders over the past five years. Last year’s per share loss of (-$1.57) was, by far, the smallest in the company’s history and could serve as a signal that the company has turned the corner.

One must always be on the lookout for equity diluting events when it comes to biotech firms and Strata Skin Sciences, Inc. (NASDAQ:SSKN) is no exception. In 2012 there were 620,000 shares outstanding. That number has increased every year and for 2016 was listed at 2.12 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SSKN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.